Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacists improve outcomes but often can’t bill for it, making billing parity key to growing services.
|Articles|March 1, 2005
March FDA Pipeline
New approvals and actions in brief
Advertisement
The meningococcal (Groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra, Sanofi Pasteur) was approved for protection against meningococcal disease in adolescents and adults aged 11 to 55 years.
FDA approved mometasone (Nasonex, Schering-Plough) for the treatment of nasal polyps in patients aged 18 years and older.
Advertisement
Related to this article
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacy should be treated as a clinical service line, not just a 340B financial workhorse.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicaid can't opt out of gene therapies, so planning matters more, says Katelyn Meyer, Pharm.D. | AMCP Nexus 2026
2
How common is atopic dermatitis in the US? Not nearly as common as other research has shown, according to this study
3
5 things you should know about the midterms and healthcare
4
Lower fitness tied to persistent fatty liver disease in teen boys with obesity
5